CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Merck KGaA (MKKGY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Merck KGaA (MKKGY)

Pharmaceutical Preparations · market cap $65.8B · as of 2026-07-14

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-24 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Merck KGaA (MKKGY) is a German science and technology company operating in pharmaceuticals, life science tools, and performance materials, with 59,077 employees and a market cap of approximately $72.4 billion. Its pharmaceutical pipeline spans oncology, fertility, neurology, and endocrinology, with several assets in Phase 2–3. The facts provided are sparse on financials, upcoming catalysts, and recent data readouts, limiting near-term visibility.
The catalyst path
  • 2026-11-24 (est.)Phase 3 · Avelumabimp 9/10
  • 2027-01-15 (est.)Phase 2 · Bintrafusp alfaimp 7/10
  • 2027-09-30 (est.)Phase 3 · Cetrorelix acetateimp 9/10
  • 2027-11-15 (est.)Phase 2 · Mirdametinibimp 7/10
Pipeline
AssetPhaseIndication
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)Phase 2Infertility Implantation Failure
Saizen®Phase 3Idiopathic Short Stature
GONAL-f®Phase 3Infertility
AS900672-EnrichedPhase 2Infertility
Follitropin alfa 150 international unit (IU)Phase 2Infertility
Pergoveris®Phase 3Assisted Reproductive Techniques
5FluorouracilPhase 3Metastatic Colorectal Cancer
Racemate Praziquantel ODTPhase 2Schistosomiasis
Recombinant human chorionic gonadotropin (r-hCG)Phase 3Assisted Reproductive Techniques
Enpatoran high dosePhase 2Systemic Lupus Erythematosus
Enpatoran medium dosePhase 2Systemic Lupus Erythematosus
Avelumab InjectionPhase 2Gestational Trophoblastic Neoplasias (GTN)
Rebif New Formulation + ibuprofen PRNPhase 3Relapsing Multiple Sclerosis
Levo Praziquantel ODTPhase 2Schistosomiasis
NKTR-255Phase 2Locally Advanced or Metastatic Urothelial Carcinoma
F0434Phase 3Diabetic Neuropathies
MSJ-0011Phase 3Anovulation
Chemotherapy + Immunotherapy InductionPhase 2Muscle-invasive Bladder Cancer
Immunotherapy MaintenancePhase 2Muscle-invasive Bladder Cancer
Recombinant Human Choriogonadotropin (r-hCG)Phase 3Polycystic Ovarian Syndrome
Price & technical context
3-month
+4.2%
6-month
+19.4%
12-month
+17.1%
52-wk range
$23.82–$34.10
vs 50-day MA
+3.9%
vs 200-day MA
+9.8%
Realized vol
28.9%
Max drawdown
-31.9%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for MKKGY (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.